UNITY Biotechnology Reports Granting of New Employment …
2 days ago · SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...
UNITY Biotechnology Announces Appointment of Federico …
3 days ago · SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging ...
UNITY Biotechnology Announces Appointment of Federico …
SAN FRANCISCO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today strengthened the executive leadership team with the appointment of Federico Grossi, M.D., Ph.D., as chief medical officer. Dr. Grossi brings a wealth of experience in clinical development and ...
Unity Biotechnology Names Federico Grossi Chief Medical …
3 days ago · (RTTNews) - Shares of Unity Biotechnology, Inc. (UBX) are gaining 9% in the pre-market trading after it has announced the appointment of Federico Grossi as Chief Medical Officer.
Unity Biotechnology, Inc. (UBX) Latest Stock News & Headlines
Get the latest Unity Biotechnology, Inc. (UBX) stock news and headlines to help you in your trading and investing decisions.
Unity Biotechnology Inc. - MarketWatch
Jan 3, 2025 · UBX | Complete Unity Biotechnology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
UNITY Biotechnology Reports Granting of New Employment
2 days ago · SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse ...
UNITY Biotechnology Announces Results from Phase 2 …
Mar 27, 2023 · UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.
UNITY Biotech Appoints SYFOVRE Developer Dr. Grossi as CMO …
3 days ago · UNITY Biotechnology strengthens leadership with Federico Grossi, former Apellis CMO who led SYFOVRE approval, as company approaches Phase 2b ASPIRE trial readout for UBX1325. ... UBX Latest News. Nov 4, 2024. UNITY Biotechnology, Inc. Reports Third Quarter 2024 Financial Results and Business Updates. Sep 24, 2024.
Release Details - Unity Biotechnology
Apr 15, 2024 · UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases.